After two giddy years of continuous growth, biotech got a rude awakening in late 2015, but many remain confident in the sector's growth potential, writes Andrew McConaghie.
Immunocore, a UK-based biotech specialising in T-cell receptor drugs has raised $320 million (£205 million), making it Europe's largest private life sciences financing.
